This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
News

NICE recommends new biological therapy for treating atopic dermatitis

The National Institute for Health and Care Excellence (NICE) has recommended dupilumab (Dupixent) as a treatment option for moderate to severe atopic dermatitis.

Dupilumab is recommended for the treatment of adults with moderate to severe atopic dermatitis in case of inadequate response, intolerance or contraindication to at least 1 other systemic therapy, including ciclosporin, methotrexate, azathioprine and mycophenolate mofetil.

Recommended dose for dupilumab (with or without topical corticosteroids) is 600 mg (2×300 mg injections) administered subcutaneously, followed by 300 mg every other week. Topical calcineurin inhibitors may be used but should be limited only to problem areas including face, neck, intertriginous and genital areas. Therapy should be discontinued if atopic dermatitis has not responded adequately after 16 weeks. An adequate response is defined as a 50% reduction in Eczema Area and Severity Index score or a 4-point reduction in Dermatology Life Quality Index.

The drug is to be used only when provided by the company in agreement with the commercial arrangement. The recommendations should not affect patients whose treatment with the drug started before publication of the guidance.


References


YOU MAY ALSO LIKE